Covalon expanding medical products distribution in Middle East

Covalon Technologies Ltd. is expanding into several Middle Eastern countries.
Covalon Technologies Ltd. is expanding into several Middle Eastern countries.

Canadian company Covalon Technologies Ltd. is expanding into several Middle Eastern countries with Qatar positioned to benefit from the advanced medical care products firm’s newly established presence. 

Covalon develops and markets next-generation wound care applications for infection management. The Ontario- based firm recently expanded its distribution in the Middle East, with Iran and the United Arab Emirates also on the company’s list of potential clients.

 “Our success in Saudi Arabia has opened the doors for Covalon to capture market share in other important countries in the Middle East,” Covalon CEO Brian Pedlar said. “These additional markets have the opportunity to significantly increase our business in the region.”

Hamad Medical Corporation operates Qatar's secondary and tertiary care system comprised of five specialty and three community hospitals. With Hamad’s assistance, Covalon's signature product, ColActive Plus Ag, passed a trial period in Qatar’s hospital system with flying colors, enabling Covalon to advance to the next step.

Now, Covalon has entered an agreement to distribute a full product line for Qatar’s health care facilities and is completing a similar process with Abu Dhabi, extending its product availability to primary care centers as well as blood banks.

Hamed Abbasian, Covalon’s vice president for business development, described ColActive Plus Ag as highly successful in treating hard-to-heal lesions, noting that it has been used in Iran since 2011.

“(It) is considered as one of the most efficacious dressings for the treatment of chronic wounds,” Abbasian said. “We have entered into a distribution agreement to expand the distribution of our ColActive Plus Ag product and to provide Covalon’s IV Clear, SurgiClear, and CovaWound (additional) product lines.”

When used together, ColActive and CovaWound promote rapid closure and healing. Abbasian indicated that the product line will benefit patients in Qatar, which has in the past been a relatively underserved market.

“With key opinion leaders … supporting the launch of our infection management and wound care products into the market, we see the opportunity for all of Covalon’s products to be category leaders,” he said.




Top